Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SNPHY
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Relative Strength
SNPHY
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
OTC
-0.29Ā ( -2.80%)
Relative Strenght
Volume Buzz
-93%
Earning Acce
No
Dist 52w H.
22%Earnings Growth
YoY
Current
Estimates
Q1.23
-86%
0.02
vsĀ 0.16
Q2.23
+56%
0.19
vsĀ 0.12
Q3.23
+131%
0.16
vsĀ -0.52
Q4.23
+24%
0.15
vsĀ 0.12
Q1.24
-98%
0
vsĀ 0.02
Q2.24
-5%
0.18
vsĀ 0.19
Q3.24
-100%
NA
vsĀ 0.16
Q4.24
N/A
NA
vsĀ 0.15
Q1.25
+33315%
0.18
vsĀ 0
Q2.25
-35%
0.12
vsĀ 0.18
Sales Growth
YoY
Current
Estimates
Q3.23
+16%
73.4BĀ vsĀ 63.4B
Q4.23
+9%
77BĀ vsĀ 70.9B
Q1.24
0%
79.1BĀ vsĀ 79.3B
Q2.24
+3%
74.8BĀ vsĀ 72.4B
Q3.24
-2%
71.6BĀ vsĀ 73.4B
Q4.24
-1%
76.4BĀ vsĀ 77B
Q1.25
-2%
77.2BĀ vsĀ 79.1B
Q2.25
-8%
68.7BĀ vsĀ 74.8B
Q3.25
+14545%
10490.7BĀ vsĀ 71.6B
Q4.25
+15178%
11667.8BĀ vsĀ 76.4B
Return on Equity
QoQ
Q1.23
+0%
0
vsĀ 0.02
Q2.23
+3%
0.03
vsĀ 0
Q3.23
+3%
0.03
vsĀ 0.03
Q4.23
+2%
0.02
vsĀ 0.03
Q1.24
+0%
0
vsĀ 0.02
Q2.24
+3%
0.03
vsĀ 0
Q3.24
+3%
0.03
vsĀ 0.03
Q4.24
+3%
0.03
vsĀ 0.03
Q1.25
+3%
0.03
vsĀ 0.03
Q2.25
+2%
0.02
vsĀ 0.03
Institutionnal Ownership
QoQ
Q1.23
NA
NA
vsĀ NA
NA
Q2.23
1
1
vsĀ NA
NA
Q3.23
1
1
vsĀ 1
NA
Q4.23
1
1
vsĀ 1
NA
Q1.24
2
2
vsĀ 1
100%
Q2.24
2
2
vsĀ 2
NA
Q3.24
2
2
vsĀ 2
NA
Q4.24
3
3
vsĀ 2
50%
Q1.25
2
2
vsĀ 3
-33%
Q2.25
2
2
vsĀ 2
NA
Forecast
66754%2026-Revenue
2026-EPS
67776%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
No Data Available